Search: onr:"swepub:oai:lup.lub.lu.se:252b1123-0add-435c-b8df-75987f97e0ac" > Anaplastic thyroid ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05303naa a2200745 4500 | |
001 | oai:lup.lub.lu.se:252b1123-0add-435c-b8df-75987f97e0ac | |
003 | SwePub | |
008 | 160401s2002 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:1951485 | |
024 | 7 | a https://lup.lub.lu.se/record/1090242 URI |
024 | 7 | a https://doi.org/10.1038/sj.bjc.66003612 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19514852 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Tennvall, Janu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-jte |
245 | 1 0 | a Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. |
264 | c 2002-06-11 | |
264 | 1 | b Springer Science and Business Media LLC,c 2002 |
520 | a Patients with anaplastic thyroid carcinoma can rarely be cured, but every effort should be made to prevent death due to suffocation. Between 1984 and 1999, 55 consecutive patients with anaplastic thyroid carcinoma were prospectively treated according to a combined regimen consisting of hyperfractionated radiotherapy, doxorubicin, and when feasible surgery. Radiotherapy was carried out for 5 days a week. The daily fraction until 1988 was 1.0 Gyx2 (A) and 1989-92 1.3 Gyx2 (B). Thereafter 1.6 Gyx2 (C) was administered. Radiotherapy was administered to a total target dose of 46 Gy; of which 30 Gy was administered preoperatively in the first two protocols (A and B), while the whole dose was given preoperatively in the third protocol (C). The therapy was otherwise identical. Twenty mg doxorubicin was administered intravenously weekly. Surgery was possible in 40 patients. No patient failed to complete the protocol due to toxicity. In only 13 cases (24%) was death attributed to local failure. Five patients (9%) 'had a survival' exceeding 2 years. No signs of local recurrence were seen in 33 patients (60%); 5 out of 16 patients in Protocol A, 11 out of 17 patients in Protocol B, 17 out of 22 patients in Protocol C (P=0.017). In the 40 patients undergoing additional surgery, no signs of local recurrence were seen in 5 out of 9 patients, 11 out of 14 patients and 17 out of 17 patients, respectively (P=0.005). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a Neoplasm Recurrence | |
653 | a Middle Age | |
653 | a Male | |
653 | a Lung Neoplasms : secondary | |
653 | a Human | |
653 | a Female | |
653 | a Feasibility Studies | |
653 | a Doxorubicin : therapeutic use | |
653 | a Dose Fractionation | |
653 | a Combined Modality Therapy | |
653 | a Clinical Protocols | |
653 | a Carcinoma : therapy | |
653 | a Carcinoma : pathology | |
653 | a Carcinoma : mortality | |
653 | a Anthracycline : therapeutic use | |
653 | a Antibiotics | |
653 | a 80 and over | |
653 | a Aged | |
653 | a Local | |
653 | a Postoperative Care | |
653 | a Prospective Studies | |
653 | a Quality of Life | |
653 | a Survival Rate | |
653 | a Thyroid Neoplasms : mortality | |
653 | a Thyroid Neoplasms : pathology | |
653 | a Thyroid Neoplasms : therapy | |
700 | 1 | a Lundell, Gu Karolinska Institutet4 aut |
700 | 1 | a Wahlberg, Peteru Lund University,Lunds universitet,Öron-, näs- och halssjukdomar, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Otorhinolaryngology (Lund),Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onh-pwa |
700 | 1 | a Bergenfelz, Andersu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-abe |
700 | 1 | a Grimelius, L4 aut |
700 | 1 | a Åkerman, Månsu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-mak |
700 | 1 | a Hjelm Skog, A-L4 aut |
700 | 1 | a Wallin, Gu Karolinska Institutet4 aut |
710 | 2 | a Bröstcancer-genetikb Sektion I4 org |
773 | 0 | t British Journal of Cancerd : Springer Science and Business Media LLCg 86:12, s. 1848-1853q 86:12<1848-1853x 1532-1827x 0007-0920 |
856 | 4 | u http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12085174&dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1038/sj.bjc.6600361y FULLTEXT |
856 | 4 | u https://doi.org/10.1038/sj.bjc.6600361 |
856 | 4 8 | u https://lup.lub.lu.se/record/109024 |
856 | 4 8 | u https://doi.org/10.1038/sj.bjc.6600361 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1951485 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view